Adaptive Biotechnologies Corp Stock Performance
| ADPT Stock | USD 16.04 0.50 3.22% |
On a scale of 0 to 100, Adaptive Biotechnologies holds a performance score of 6. The firm shows a Beta (market volatility) of 0.0753, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Adaptive Biotechnologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Adaptive Biotechnologies is expected to be smaller as well. Please check Adaptive Biotechnologies' coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Adaptive Biotechnologies' price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Adaptive Biotechnologies Corp are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Adaptive Biotechnologies unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.22 | Five Day Return (9.99) | Year To Date Return 0.82 | Ten Year Return (60.20) | All Time Return (60.20) |
1 | Disposition of 133032 shares by Sharon Benzeno of Adaptive Biotechnologies at 8.46 subject to Rule 16b-3 | 11/20/2025 |
2 | Adaptive Biotechnologies Is Up 15.4 percent After Raising Guidance on Strong MRD Test Momentum Has the Bull Case Changed | 11/21/2025 |
3 | Disposition of 124998 shares by Robins Chad M of Adaptive Biotechnologies at 18.94 subject to Rule 16b-3 | 12/01/2025 |
4 | Adaptive Biotechnologies Valuation Check After ASH clonoSEQ Data Spotlight and Q3 Earnings Beat | 12/08/2025 |
5 | Disposition of 19423 shares by Francis Lo of Adaptive Biotechnologies at 8.46 subject to Rule 16b-3 | 12/17/2025 |
6 | Disposition of 2194 shares by Francis Lo of Adaptive Biotechnologies at 8.46 subject to Rule 16b-3 | 12/22/2025 |
7 | Acquisition by Francis Lo of 1100 shares of Adaptive Biotechnologies at 3.99 subject to Rule 16b-3 | 12/29/2025 |
8 | Disposition of 3125 shares by Francis Lo of Adaptive Biotechnologies at 3.99 subject to Rule 16b-3 | 01/02/2026 |
9 | Disposition of 124998 shares by Robins Chad M of Adaptive Biotechnologies at 15.59 subject to Rule 16b-3 | 01/05/2026 |
10 | Disposition of 10000 shares by Harlan Robins of Adaptive Biotechnologies at 16.44 subject to Rule 16b-3 | 01/06/2026 |
11 | Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026 | 01/13/2026 |
12 | First Week of March 20th Options Trading For Adaptive Biotechnologies - Nasdaq | 01/16/2026 |
13 | Guggenheim Raises Price Target for ADPT to 21, Maintains Buy Rating ADPT Stock News - GuruFocus | 01/26/2026 |
14 | Disposition of 124998 shares by Robins Chad M of Adaptive Biotechnologies at 18.44 subject to Rule 16b-3 | 02/02/2026 |
15 | Adaptive Biotechnologies Cut to Hold at Wall Street Zen | 02/03/2026 |
16 | Disposition of 2145 shares by Kyle Piskel of Adaptive Biotechnologies at 12.14 subject to Rule 16b-3 | 02/04/2026 |
17 | Adaptive Biotechnologies Insider Harlan Robins Sells 34,668 Shares | 02/05/2026 |
18 | Adaptive Biotechnologies targets 30 clonoSEQ test volume growth in 2026 while expanding margins and data partnerships | 02/06/2026 |
19 | Disposition of 10000 shares by Harlan Robins of Adaptive Biotechnologies at 16.61 subject to Rule 16b-3 | 02/12/2026 |
| Begin Period Cash Flow | 68 M | |
| Total Cashflows From Investing Activities | 77.8 M |
Adaptive Biotechnologies Relative Risk vs. Return Landscape
If you would invest 1,371 in Adaptive Biotechnologies Corp on November 16, 2025 and sell it today you would earn a total of 233.00 from holding Adaptive Biotechnologies Corp or generate 16.99% return on investment over 90 days. Adaptive Biotechnologies Corp is currently generating 0.3697% in daily expected returns and assumes 4.8093% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Adaptive, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adaptive Biotechnologies Target Price Odds to finish over Current Price
The tendency of Adaptive Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 16.04 | 90 days | 16.04 | about 67.96 |
Based on a normal probability distribution, the odds of Adaptive Biotechnologies to move above the current price in 90 days from now is about 67.96 (This Adaptive Biotechnologies Corp probability density function shows the probability of Adaptive Stock to fall within a particular range of prices over 90 days) .
Adaptive Biotechnologies Price Density |
| Price |
Predictive Modules for Adaptive Biotechnologies
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Adaptive Biotechnologies. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Adaptive Biotechnologies Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Adaptive Biotechnologies is not an exception. The market had few large corrections towards the Adaptive Biotechnologies' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Adaptive Biotechnologies Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Adaptive Biotechnologies within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.22 | |
β | Beta against Dow Jones | 0.08 | |
σ | Overall volatility | 1.65 | |
Ir | Information ratio | 0.04 |
Adaptive Biotechnologies Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Adaptive Biotechnologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Adaptive Biotechnologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Adaptive Biotechnologies had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 276.98 M. Net Loss for the year was (159.59 M) with profit before overhead, payroll, taxes, and interest of 111.85 M. | |
| Adaptive Biotechnologies Corp currently holds about 383.74 M in cash with (95.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Adaptive Biotechnologies has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 10000 shares by Harlan Robins of Adaptive Biotechnologies at 16.61 subject to Rule 16b-3 |
Adaptive Biotechnologies Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Adaptive Stock often depends not only on the future outlook of the current and potential Adaptive Biotechnologies' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Adaptive Biotechnologies' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 151.7 M | |
| Cash And Short Term Investments | 227 M |
Adaptive Biotechnologies Fundamentals Growth
Adaptive Stock prices reflect investors' perceptions of the future prospects and financial health of Adaptive Biotechnologies, and Adaptive Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adaptive Stock performance.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.0679 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 2.25 B | ||||
| Shares Outstanding | 153.78 M | ||||
| Price To Earning | 0.25 X | ||||
| Price To Book | 10.98 X | ||||
| Price To Sales | 8.63 X | ||||
| Revenue | 276.98 M | ||||
| Gross Profit | 111.85 M | ||||
| EBITDA | (29.85 M) | ||||
| Net Income | (159.59 M) | ||||
| Cash And Equivalents | 383.74 M | ||||
| Cash Per Share | 2.69 X | ||||
| Total Debt | 280.58 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 3.93 X | ||||
| Book Value Per Share | 1.42 X | ||||
| Cash Flow From Operations | (95.21 M) | ||||
| Earnings Per Share | (0.39) X | ||||
| Market Capitalization | 2.39 B | ||||
| Total Asset | 512.74 M | ||||
| Retained Earnings | (1.36 B) | ||||
| Working Capital | 185.7 M | ||||
| Current Asset | 118.69 M | ||||
| Current Liabilities | 59.26 M | ||||
About Adaptive Biotechnologies Performance
Assessing Adaptive Biotechnologies' fundamental ratios provides investors with valuable insights into Adaptive Biotechnologies' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Adaptive Biotechnologies is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 50.23 | 47.72 | |
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.14) | (0.14) | |
| Return On Assets | (0.12) | (0.12) | |
| Return On Equity | (0.27) | (0.29) |
Things to note about Adaptive Biotechnologies performance evaluation
Checking the ongoing alerts about Adaptive Biotechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adaptive Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adaptive Biotechnologies had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 276.98 M. Net Loss for the year was (159.59 M) with profit before overhead, payroll, taxes, and interest of 111.85 M. | |
| Adaptive Biotechnologies Corp currently holds about 383.74 M in cash with (95.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.69. | |
| Adaptive Biotechnologies has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 10000 shares by Harlan Robins of Adaptive Biotechnologies at 16.61 subject to Rule 16b-3 |
- Analyzing Adaptive Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adaptive Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Adaptive Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adaptive Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adaptive Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adaptive Biotechnologies' stock. These opinions can provide insight into Adaptive Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Adaptive Stock Analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.